Novocure Announces Upcoming Investor Events
NVCRBAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) announced today that management will participate in three upcoming investor events. 2025 Wells Fargo Healthcare Conference, September 4, 2025: Ashley Cordova, Chief Executive Officer, will take part in a fireside chat at 9:30 a.m. ET, as well as one-on-one meetings with investors throughout the event. H.C. Wainwright 27th Annual Global Investment Conference, September 9, 2025: Ms. Cordova will take part in a fireside chat at 2:00 p.m.
Novocure Submits Premarket Approval Application to FDA for Tumor Treating Fields Therapy in Locally Advanced Pancreatic Cancer
NVCRBAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today announced it submitted a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Tumor Treating Fields (TTFields) therapy for the treatment of locally advanced pancreatic cancer. This submission is supported by the PANOVA-3 trial, which evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel (GnP) as a first-line treatment for adults with unresectable, locally advanc
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial
NVCRTTField therapy with chemotherapy improved median overall and pain-free survival in pancreatic cancer, according to new data from the PANOVA-3 trial.
Reported Sunday, Zai Lab And Novocure Announce PANOVA-3 Results: TTFields Therapy Achieves Median OS Of 16.2 Months With Significant Gains In Quality Of Life And Pain Control
NVCRNovoCure Warns Of Potential $11 Million Tariff Hit If US Trade Pause Expires In 2025
NVCRNovoCure posted a smaller-than-expected Q1 loss with 12% revenue growth, while monitoring tariff shifts that could impact 2025 costs.
NovoCure Q1 EPS $(0.31) Beats $(0.46) Estimate, Sales $154.99M Beat $146.60M Estimate
NVCRNovoCure's Earnings: A Preview
NVCRPiper Sandler Maintains Overweight on NovoCure, Lowers Price Target to $34
NVCRNovocure's Optune Lua Receives CE Mark Approval For Treatment If Metastatic Non-Small Cell Lung Cancer
NVCRWedbush Maintains Neutral on NovoCure, Lowers Price Target to $27
NVCRJP Morgan Maintains Neutral on NovoCure, Lowers Price Target to $28
NVCRNovoCure Reports Wider Than Expected Q4 Loss Despite 21% Jump In Sales, Expects Product Enhancements To Hit Gross Margin In 2025
NVCRNovoCure's Q4 revenue rose 21% to $161.27M, surpassing expectations, while its loss widened. Annual sales hit $605M, fueled by Optune Gio's expansion.
NovoCure Q4 2024 GAAP EPS $(0.61) Misses $(0.34) Estimate, Sales $161.27M Beat $157.81M Estimate
NVCRDeep Dive Into NovoCure Stock: Analyst Perspectives (7 Ratings)
NVCRHC Wainwright & Co. Reiterates Buy on NovoCure, Maintains $38 Price Target
NVCRNovocure Reports Preliminary Net Revenues For Q4 Of $161.3M, Up 21% YoY Compared To Consensus Of $153.052M
NVCRNovocure Reports Preliminary Net Revenues For FY2024 Of $605.2M, Up 19% YoY Compared To Consensus Of $594.9M
NVCRHC Wainwright & Co. Reiterates Buy on NovoCure, Maintains $30 Price Target
NVCRNovoCure: Q1 Earnings Insights
NVCRNovoCure (NASDAQ:NVCR) reported its Q1 earnings results on Thursday, April 28, 2022 at 06:00 AM.
Here's what investors need to know about the announcement.
NovoCure Expects FY22 Active Patient Growth Of 2-5%
NVCRNovoCure Q1 EPS $(0.04) Beats $(0.18) Estimate, Sales $137.50M Beat $134.08M Estimate
NVCR